About
Robert Lasser, MD, is affiliated with Sage Therapeutics in Cambridge, Massachusetts. His publications from 2013 to 2023 focus on the treatment of major depressive disorder (MDD), including studies on zuranolone and lisdexamfetamine dimesylate. He has contributed to research on the safety, efficacy, and symptom management of depression, with particular attention to women and postpartum depression. His work often involves clinical trials and collaboration with co-authors such as Andrew J. Cutler and Stephen J. Kanes.
